Towards A Universal Lipid Nanoparticle (LNP) Platform For Multiplex Engineering Of Next-Generation Ex Vivo Cell Therapies

Multiplex genetic engineering is becoming essential for advancing ex vivo cell therapies against solid tumors, where T cells must overcome a suppressive tumor microenvironment while meeting strict safety requirements. Achieving simultaneous CAR expression alongside targeted gene knockouts—particularly to reduce graft-versus-host disease risk—demands delivery strategies capable of handling multiple nucleic acid types at once. Conventional viral vectors and electroporation often fall short, especially when efficiency, safety, and scalability must align. Lipid nanoparticle (LNP) platforms are emerging as a promising alternative, offering a flexible approach for co-delivering RNA and DNA to primary T cells.

Discover how evolving LNP technologies are reshaping what’s possible in complex cell engineering and opening new pathways for more effective, scalable immunotherapies.